Rezolute (RZLT) Other Accumulated Expenses (2014 - 2023)
Rezolute (RZLT) posted Other Accumulated Expenses of $1.1 million for Q1 2023, up 4.67% sequentially from $1.1 million in Q4 2022, and up 46.73% YoY from $764000.0 in Q1 2022.
Analysis
Rezolute (RZLT) Other Accumulated Expenses (2014 - 2023) Analysis & Trends
Rezolute has reported Other Accumulated Expenses for 10 years, with the latest figure at $1.1 million in Q1 2023.
- Quarterly Other Accumulated Expenses rose 46.73% year-over-year to $1.1 million in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $1.1 million (up 46.73% YoY) and the FY2022 annual result came in at $243000.0, changed 0.41% from the prior year.
- Other Accumulated Expenses rose to $1.1 million in Q1 2023 per RZLT's latest filing, from $1.1 million in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $1.1 million in Q1 2023 and troughed at $122000.0 in Q3 2022.
- A 5-year average of $486357.1 and a median of $388500.0 in 2020 frame the typical range for Other Accumulated Expenses.
- The sharpest annual moves came in 2019 and 2022: Other Accumulated Expenses soared 361.4% in 2019, then sank 82.03% in 2022.
- Over 5 years, Other Accumulated Expenses stood at $641000.0 in 2019, then plunged by 53.2% to $300000.0 in 2020, then surged by 59.0% to $477000.0 in 2021, then jumped by 124.53% to $1.1 million in 2022, then grew by 4.67% to $1.1 million in 2023.
- According to Business Quant data, Other Accumulated Expenses over the past three periods registered $1.1 million, $1.1 million, and $122000.0 for Q1 2023, Q4 2022, and Q3 2022 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Rezolute | 477.02 Mn | 477.02 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2023 | 1.12 Mn |
| Dec 31, 2022 | 1.07 Mn |
| Sep 30, 2022 | 1.09 Mn |
| Jun 30, 2022 | 979,000.00 |
| Mar 31, 2022 | 764,000.00 |
| Dec 31, 2021 | 477,000.00 |
| Sep 30, 2021 | 679,000.00 |
| Jun 30, 2021 | 349,000.00 |
| Mar 31, 2021 | 469,000.00 |
| Dec 31, 2020 | 543,000.00 |
| Sep 30, 2020 | 300,000.00 |
| Jun 30, 2020 | 188,000.00 |
| Mar 31, 2020 | 284,000.00 |
| Dec 31, 2019 | 641,000.00 |
| Sep 30, 2019 | 159,000.00 |
| Jun 30, 2019 | 526,000.00 |
| Sep 30, 2018 | 132,922.00 |
| Jun 30, 2018 | 114,000.00 |
| Mar 31, 2018 | 121,705.00 |
| Dec 31, 2017 | 116,234.00 |